BioCentury

7:00 AM GMT, May 30, 2005
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Reading between the lines

Based on data reported last week, investors concluded that Lucentis from Genentech Inc. and Novartis AG will be the winner over Eyetech Inc.'s Macugen in the treatment of wet age-related macular degeneration (AMD). But EYET is arguing that the patient populations and protocols in the studies - and by extension the results - are not comparable.

DNA (South San Francisco, Calif.) and Novartis (NVS; SWX:NOVN, Basel, Switzerland) reported that after one year, about 95% of patients given Lucentis ranibizumab in a Phase III trial lost less than 15 ETDRS letters, or 3 lines, in visual acuity compared to about 62% in the control arm, the primary endpoint (p<0.0001).

Patients given Lucentis also significantly improved mean visual acuity, a secondary endpoint, while controls experienced a decrease.

Patients in the

Read the full 1285 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.